Mendell JR, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013;48:21–6.
Google Scholar
Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.
Google Scholar
Bhat HF, Mir SS, Dar KB, Bhat ZF, Shah RA, Ganai NA. ABC of multifaceted dystrophin glycoprotein complex (DGC). J Cell Physiol. 2018;233:5142–59.
Google Scholar
Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345:315–9.
Google Scholar
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.
Google Scholar
Wang D, Zhong L, Nahid MA, Gao G. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv. 2014;11:345–64.
Google Scholar
Rivera VM, Gao G, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 2005;105:1424–30.
Google Scholar
Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther Janv. 2010;18:80–6.
Google Scholar
Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253–61.
Google Scholar
Athanasopoulos T, Graham I, Foster H, Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther. 2004;11:S109–21.
Google Scholar
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731–40.
Google Scholar
Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12:787–9.
Google Scholar
Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K, et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 Gene Transfer. Mol Ther. 2008;16:1825–32.
Google Scholar
Bostick B, Yue Y, Lai Y, Long C, Li D, Duan D. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther. 2008;19:851–6.
Google Scholar
Yue Y, Pan X, Hakim CH, Kodippili K, Zhang K, Shin J-H, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet. 2015;24:5880–90.
Google Scholar
Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.
Google Scholar
Hakim CH, Wasala NB, Pan X, Kodippili K, Yue Y, Zhang K, et al. A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA/2J-mdx model of duchenne muscular dystrophy. Mol Ther Methods Clin Dev. 2017;6:216–30.
Google Scholar
Duan D, Systemic AAV. Micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther. 2018;26:2337–56.
Google Scholar
Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119:624–35.
Google Scholar
Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther. 2008;16:657–64.
Google Scholar
Shin J-H, Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Kinoshita K, Chiyo T. et al. Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther. 2011;18:910–9.
Google Scholar
Bostick B, Shin J-H, Yue Y, Duan D. AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther. 2011;19:1826–32.
Google Scholar
Wang B, Li J, Fu FH, Xiao X. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthopaedic Res. 2009;27:421–6.
Guiner CL, McIntyre M, Larcher T, Adjali O, Lafoux A, Toumaniantz G, et al. Dose finding study in the DMDmdx rat model to determine the efficacious dose of a rAAV9 vector encoding a human mini-dystrophin after IV administration. Neuromuscular Disorders. 2017;27:S188.
Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020;77:1122–31.
Google Scholar
Moorehead T, Yong F, Neelakantan S, Beaverson K, Binks M. Safety and tolerability of PF-06939926 in ambulatory boys with duchenne muscular dystrophy: a phase 1b multicenter, open- label, dose ascending study. Mol Ther J Am Soc Gene Ther. 2020;28:272.
Koo T. Studies on gene transfer in skeletal muscle cells and tissues using recombinant adeno-associated virus (AAV) vectors. Thesis. 2010.
Suzuki A, Yoshida M, Ozawa E. Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J Cell Biol. 1995;128:373–81.
Google Scholar
Sadoulet-Puccio HM, Rajala M, Kunkel LM. Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci USA. 1997;94:12413–8.
Google Scholar
Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet. 2000;9:1033–40.
Google Scholar
Bhat HF, Adams ME, Khanday FA. Syntrophin proteins as Santa Claus: role(s) in cell signal transduction. Cell Mol Life Sci. 2013;70:2533–54.
Google Scholar
Matamoros M, Pérez-Hernández M, Guerrero-Serna G, Amorós I, Barana A, Núñez M, et al. Nav1.5 N-terminal domain binding to α1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels. Cardiovasc Res. 2016;110:279–90.
Google Scholar
Leyva-Leyva M, Sandoval A, Felix R, González-Ramírez R. Biochemical and functional interplay between ion channels and the components of the dystrophin-associated glycoprotein complex. J Membr Biol. 2018;251:535–50.
Google Scholar
Sabourin J, Lamiche C, Vandebrouck A, Magaud C, Rivet J, Cognard C, et al. Regulation of TRPC1 and TRPC4 cation channels requires an α1-syntrophin-dependent complex in skeletal mouse myotubes. J Biol Chem. 2009;284:36248–61.
Google Scholar
Vandebrouck A, Sabourin J, Rivet J, Balghi H, Sebille S, Kitzis A, et al. Regulation of capacitative calcium entries by alpha1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha1-syntrophin. FASEB J. 2007;21:608–17.
Google Scholar
Dombernowsky NW, Ölmestig JNE, Witting N, Kruuse C. Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies – Still a possible treatment modality? Neuromuscul Disord. 2018;28:914–26.
Google Scholar
Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin cooh-terminal domain. J Cell Biol. 2000;150:1399–410.
Google Scholar
Koo T, Malerba A, Athanasopoulos T, Trollet C, Boldrin L, Ferry A, et al. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-Terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice. Hum Gene Ther. 2011;22:1379–88.
Google Scholar
McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8:195–213.
Google Scholar
Tandon A, Jefferies JL, Villa CR, Hor KN, Wong BL, Ware SM, et al. Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging. Am J Cardiol. 2015;115:967–71.
Google Scholar
Johnson EK, Zhang L, Adams ME, Phillips A, Freitas MA, Froehner SC, et al. Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. PLoS ONE. 2012;7:e43515.
Google Scholar
Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, François V, et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE. 2014;9:e110371.
Google Scholar
Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol. 1999;17:241–5.
Google Scholar
D’Costa S, Blouin V, Broucque F, Penaud-Budloo M, François A, Perez IC, et al. Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev. 2016;5:16019.
Google Scholar
Salvetti A, Orève S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther. 1998;9:695–706.
Google Scholar
Shinoda K, Tomita M, Ishihama Y. emPAI Calc—for the estimation of protein abundance from large-scale identification data by liquid chromatography-tandem mass spectrometry. Bioinformatics. 2010;26:576–7.
Google Scholar
Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1265–72.
Google Scholar
Fraysse B, Desaphy J-F, Rolland J-F, Pierno S, Liantonio A, Giannuzzi V, et al. Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone. Neurobiol Dis. 2006;21:372–80.
Google Scholar
Louch WE, Sheehan KA, Wolska BM. Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol. 2011;51:288–98.
Google Scholar
Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–50.
Google Scholar
Dyle MC, Ebert SM, Cook DP, Kunkel SD, Fox DK, Bongers KS, et al. Systems-based discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. J Biol Chem. 2014;289:14913–24.
Google Scholar
Moorwood C, Liu M, Tian Z, Barton ER. Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies. J Vis Exp. 2013;31:e50036.
Chapdelaine P, Gérard C, Sanchez N, Cherif K, Rousseau J, Ouellet DL, et al. Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice. Gene Ther. 2016;23:606–14.
Google Scholar
Mayra A, Tomimitsu H, Kubodera T, Kobayashi M, Piao W, Sunaga F, et al. Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles. Biochem Biophys Res Commun. 2011;405:204–9.
Google Scholar
Madhavan R, Jarrett HW. Phosphorylation of dystrophin and alpha-syntrophin by Ca(2+)-calmodulin dependent protein kinase II. Biochim Biophys Acta. 1999;1434:260–74.
Google Scholar
Madhavan R, Jarrett HW. Calmodulin-activated phosphorylation of dystrophin. Biochemistry. 1994;33:5797–804.
Google Scholar
Sato S, Omori Y, Katoh K, Kondo M, Kanagawa M, Miyata K, et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci. 2008;11:923–31.
Google Scholar
Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006;99:e3–9.
Google Scholar
Banks GB, Judge LM, Allen JM, Chamberlain JS. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 2010;6:e1000958.
Google Scholar
Lorin C, Vögeli I, Niggli E. Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage. Cardiovasc Res. 2015;106:153–62.
Google Scholar
Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev. 1997;77:901–30.
Google Scholar
Hermans MCE, Pinto YM, Merkies ISJ, de Die-Smulders CEM, Crijns HJGM, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord. 2010;20:479–92.
Google Scholar
Szabó PL, Ebner J, Koenig X, Hamza O, Watzinger S, Trojanek S, et al. Cardiovascular phenotype of the Dmdmdx rat – a suitable animal model for Duchenne muscular dystrophy. Dis Model Mech. 2021;22:14.
England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180–2.
Google Scholar
Yue Y, Liu M, Duan D. C-Terminal-Truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol Ther. 2006;14:79–87.
Google Scholar
Nakamori M, Takahashi MP. The role of α-dystrobrevin in striated muscle. Int J Mol Sci. 2011;12:1660–71.
Google Scholar
Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies KE, Ozawa EZZ. domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum Mol Genet. 2004;13:693–702.
Google Scholar
Johnson EK, Li B, Yoon JH, Flanigan KM, Martin PT, Ervasti J, et al. Identification of new dystroglycan complexes in skeletal muscle. PLoS ONE. 2013;8:e73224.
Google Scholar
Liu L. Lessons from cavin-1 deficiency. Biochem Soc Trans. 2020;48:147–54.
Google Scholar
Taniguchi T, Maruyama N, Ogata T, Kasahara T, Nakanishi N, Miyagawa K, et al. PTRF/Cavin-1 deficiency causes cardiac dysfunction accompanied by cardiomyocyte hypertrophy and cardiac fibrosis. PLoS ONE. 2016;11:e0162513.
Google Scholar
Kaakinen M, Reichelt ME, Ma Z, Ferguson C, Martel N, Porrello ER, et al. Cavin-1 deficiency modifies myocardial and coronary function, stretch responses and ischaemic tolerance: roles of NOS over-activity. Basic Res Cardiol. 2017;112:24.
Google Scholar
Bostick B, Yue Y, Long C, Marschalk N, Fine DM, Chen J, et al. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged mdx mice. Mol Ther. 2009;17:253–61.
Google Scholar
Banks GB, Combs AC, Chamberlain JR, Chamberlain JS. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum Mol Genet. 2008;17:3975–86.
Google Scholar
Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci. 2009;40:433–41.
Google Scholar
Sawicka E. Origin of the ring muscle fibers in neuromuscular diseases. Neuropatologia Polska. 1991;29:29–40.
Google Scholar
Sekiguchi M. The role of dystrophin in the central nervous system: a mini review. Acta Myol: Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of Myology. 2005;24:93–7.
Google Scholar
Haenggi T, Fritschy J-M. Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol Life Sci: CMLS. 2006;63:1614–31.
Google Scholar
Chen L, Zhang J, Hu X, Philipson KD, Scharf SM. The Na+/Ca2+ exchanger-1 mediates left ventricular dysfunction in mice with chronic intermittent hypoxia. J Appl Physiol (1985). 2010;109:1675–85.
Google Scholar
